Please ensure Javascript is enabled for purposes of website accessibility

Is Moderna Winning on Vaccine Efficacy?

By Adria Cimino – Sep 17, 2021 at 7:00AM

Key Points

  • The Pfizer and Moderna vaccines demonstrated efficacy of more than 95% against severe disease in clinical trials.
  • A recent CDC analysis suggests the Moderna vaccine may be slipping ahead in the real world.
  • Investors should monitor various studies -- but remember the importance of clinical trial data.

Motley Fool Issues Rare “All In” Buy Alert

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

A new study shows a striking difference between the Moderna and Pfizer vaccines.

Moderna (MRNA 1.77%) and Pfizer (PFE 1.08%) hold the top spots in the coronavirus vaccine market. Both won authorization last December. Both have won orders for 500 million doses from the U.S. government. And together, they've fully vaccinated the biggest share of Americans -- 98 million by Pfizer and 67 million by Moderna. That compares to 14 million by smaller player Johnson & Johnson.

When it comes to efficacy, J&J lagged behind the leaders from the start. It reported efficacy of 85% against severe disease in clinical trials. That compares to more than 95% for Moderna and Pfizer. These makers of mRNA vaccines seem about equal. Now, though, new studies are showing us more data. One in particular suggests Moderna may be the best at keeping people out of the hospital. Does this mean Moderna's vaccine is better than Pfizer's? Let's take a closer look.

Person looking at laptop in an office after dark.

Image source: Getty Images.

Data from nine states

The Centers for Disease Control and Prevention (CDC) recently published data gathered from hospitals across nine states. Researchers looked at hospitalizations and emergency room visits from June through August. This includes more than 14,000 hospitalizations and more than 18,000 urgent care visits. The study included only individuals who were fully vaccinated with Moderna, Pfizer, or J&J vaccines.

The analysis suggests the Moderna vaccine is the most efficacious. Moderna showed vaccine effectiveness of 95% against hospitalization and 92% against urgent medical visits. That compares to 80% and 77% for Pfizer and 60% and 65% for J&J.

Does the analysis mean Moderna is rising above close rival Pfizer? Not necessarily. I'm not convinced there's a major difference between the efficacy levels of Moderna and Pfizer.

First, this particular study is just that: One study. Another recent report weighed in Moderna's favor -- but it measured something completely different. I wrote about this research, showing more antibodies produced by the Moderna vaccine. As I said in that article, higher antibody levels may not equal stronger protection. And that report can't be used to support the findings of the CDC study. Bottom line: We don't have a handful of very specific studies leading us to one conclusion.

Another detail to note: The CDC analysis didn't include partially vaccinated individuals. It also didn't consider the timing of vaccination. That's an extremely important factor. Some of those in the study may have been experiencing waning immunity. Others might have completed vaccination more recently -- and that means a higher level of protection.

So, what does this mean for investors?

We shouldn't ignore these analyses or any real-world data about vaccine performance. But we should put them into perspective. Most times, they won't offer us as much clarity as a clinical trial (unless several well-designed studies produce the same conclusion.) Companies carefully design trials so we don't have missing elements -- like the timing of vaccination -- that could affect the study outcome. That's why it's extremely important to refer to Pfizer's and Moderna's clinical trial follow-up data.

And that data is pointing to one thing: Positive performance for both vaccines. Moderna's showed 93% efficacy overall, 98.2% against severe disease, and 100% efficacy against death. In Pfizer's six-month follow up, the vaccine showed 91.3% overall efficacy and 95.3% effectiveness against severe disease.

Moderna may have a slight efficacy edge, but not enough to make a difference when it comes to vaccine orders -- or revenue. The world needs more than one vaccine maker in order to meet the need for coronavirus vaccines. There is room for a few top performers.

In recent weeks, both companies have said immunity wanes in the six to eight months following the primary series -- and boosters are needed. This, too, shows a great similarity between the performance of the two vaccines.

So, investors have reason to be positive about both Moderna and Pfizer. Prospects remain strong. Moderna expects $20 billion in vaccine revenue this year. And Pfizer and partner BioNTech say their vaccine revenue will total more than $33 billion.

Each company may slip ahead in certain areas. But overall, they both are winning in the race to protect populations against the coronavirus. And that means investors who buy the shares may win too.

Adria Cimino has no position in any of the stocks mentioned. The Motley Fool recommends Johnson & Johnson and Moderna Inc. The Motley Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Nearly 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Moderna Stock Quote
$179.03 (1.77%) $3.12
Pfizer Stock Quote
$50.67 (1.08%) $0.54
Johnson & Johnson Stock Quote
Johnson & Johnson
$178.09 (0.05%) $0.09
BioNTech Se Stock Quote
BioNTech Se
$167.67 (0.39%) $0.65

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
S&P 500 Returns

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 12/01/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.